Dr. Alkharabsheh on Future Research Directions in MPNs

Video

Omar Alkharabsheh, MD, discusses future research directions for the treatment of patients with myeloproliferative neoplasms.

Omar Alkharabsheh, MD, assistant professor of interdisciplinary clinical oncology at USA College of Medicine and a medical oncologist and hematologist at USA College of Medicine, discusses future research directions for the treatment of patients with myeloproliferative neoplasms (MPNs).

Currently, many early-phase clinical trials are examining treatment options for patients with MPNs, such as myelofibrosis, Alkharabsheh says. For example, the BCL-2 inhibitor navitoclax is being combined with JAK inhibitors in this patient population, Alkharabsheh notes. Moreover, ruxolitinib (Jakafi) induces some suppression of the JAK/STAT pathway, which could lead to improvements in symptoms and reduction in spleen size, although it does not change the biology of the disease, Alkharabsheh explains.

By adding a BCL-2 inhibitor to ruxolitinib, it is believed that the disease biology can be changed by decreasing the risk of progression to acute myeloid leukemia (AML) and improving overall survival, according to Alkharabsheh. However, this regimen will need to be further investigated in a more advanced clinical trial, Alkharabsheh concludes.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
A panel of 4 experts on chronic graft-versus-host disease
A panel of 4 experts on chronic graft-versus-host disease
Manish A. Shah, MD